HDAC6 and amyotrophic lateral sclerosis: Tubastatin A was of interest because HDAC6 inhibitors have shown beneficial effects in models of Charcot-Marie-Tooth peripheral neuropathies (Benoy et al. 2018; d'Ydewalle et al. 2011) and restored axonal transport in motor neurons derived from induced pluripotent stem cells (iPSC) from ALS patients with FUS mutation (Guo et al. 2017).